Joseph R. Young - 04 Feb 2026 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
SVP, FINANCE, CHIEF ACCT OFFCR
Signature
/s/ Joseph R. Young
Issuer symbol
VERA
Transactions as of
04 Feb 2026
Net transactions value
$0
Form type
4
Filing time
06 Feb 2026, 20:00:16 UTC
Previous filing
13 Nov 2025
Next filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR C/O VERA THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE /s/ Joseph R. Young 06 Feb 2026 0001861684

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Award $0 +10,000 +17% $0.000000 67,839 04 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (right to buy) Award $0 +20,000 $0.000000 20,000 04 Feb 2026 Class A Common Stock 20,000 $42.74 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
F2 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.